Canaan Partners
700 Fairfield AvenueStamford, CT 6902
Firm Size
- Assets Under Management (AUM):$5.5 Billion
- Number of Funds:29
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Services
Healthcare
Consumer
Description
Canaan Partners is a venture capital firm located in Stamford, CT. They focus on investing in early-stage startups, primarily in the fields of healthcare, technology, and consumer services. With over 30 years of experience, Canaan Partners has built a strong reputation as a trusted partner for entrepreneurs and investors alike. Their team of seasoned investment professionals provides both financial support and strategic guidance to their portfolio companies. They strive to identify promising startups with disruptive technologies and innovative business models that have the potential to achieve significant growth and market disruption. Canaan Partners has a global reach, investing in companies across North America, Europe, and Asia. They have made successful investments in numerous well-known companies, including Match.com, Ebates, and LendingClub. Additionally, Canaan Partners actively supports diversity and inclusion, with a dedicated initiative to back underrepresented founders and communities. In Stamford, CT, Canaan Partners has established a strong presence in the local startup ecosystem, collaborating with other venture capital firms, entrepreneurs, and industry experts. Through their investments and partnerships, they aim to foster innovation and create a thriving entrepreneurial community in the region. Overall, Canaan Partners in Stamford, CT, is a venture capital firm that provides early-stage funding and strategic support to startups in the healthcare, technology, and consumer services sectors. They have a proven track record and are actively involved in the local startup ecosystem, striving to drive innovation and growth.Latest News
Powered by
Feb 14, 2024: IPSecure Closes Multiple Seven-Figure Seed II Round of Funding and Announces Formation of Key Advisory Board
IPSecure, the leading Buy Box brand protection company for brands and e-commerce agencies, announced today that it has raised its second multi seven-figure round of funding, led by Secondary Market pioneer Manhattan Venture Partners. The company also announced that Dan Ciporin , a successful early e-commerce operator and former General Partner at Canaan Partners, Frederick Felman , Partner at Sage Partners, and William Barkow , Partner at Manhattan Venture Partners, will be joining IPSecure's Advisory Board.
Aug 10, 2023: Atmosfy Announces $12 Million in Seed Funding as it Surpasses One Million Local Businesses on the Platform
Atmosfy, the leading video platform for reviewing live dining and nightlife experiences, announced $12 million in seed funding led by Redpoint Ventures with participation from Palm Tree Crew Investments (Kygo), Streamlined Ventures, Industry Ventures, Canaan Partners, Village Global, Progression Fund and Convivialite Ventures. The funding comes as Atmosfy rapidly expands its global reach, celebrating its one-millionth local business across more than 10,000 cities in more than 150 countries.
May 18, 2023: OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The Company concurrently raised $14 million in new funding from existing investors, led by RiverVest Venture Partners and including ARCH Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest and others.
Apr 27, 2023: Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $53 million Series E equity financing. The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball . Additionally, Ms. Ball, along with Florencia Segal , M.D., and Brian Goodman , Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.